AtriCure (NASDAQ:ATRC) Director Karen Prange Sells 3,564 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Karen Prange also recently made the following trade(s):

• On Wednesday, May 20th, Karen Prange sold 3,000 shares of AtriCure stock. The shares were sold at an average price of $28.65, for a total value of $85,950.00.

AtriCure Stock Up 4.8%

ATRC opened at $41.39 on Friday. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $43.18. The business has a 50 day moving average price of $32.25 and a two-hundred day moving average price of $31.38. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The company has a market cap of $2.11 billion, a PE ratio of 197.10 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current year.

Institutional Investors Weigh In On AtriCure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure during the 2nd quarter worth $37,000. Harbor Investment Advisory LLC acquired a new stake in shares of AtriCure in the second quarter valued at about $40,000. Smartleaf Asset Management LLC boosted its holdings in AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares in the last quarter. Fifth Third Bancorp acquired a new position in AtriCure during the first quarter worth about $51,000. Finally, Global Retirement Partners LLC purchased a new position in AtriCure in the second quarter valued at about $52,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

ATRC has been the subject of several recent analyst reports. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. UBS Group cut their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Finally, Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.